Open AccessLower circulating kisspeptin and primary hypogonadism in men with type 2 diabetes
Author(s) -
AsareAnane Henry,
Ofori Emmanuel Kwaku,
KwaoZigah Genevieve,
Ateko Richmond O.,
Annan Benjamin D. R. T.,
Adjei Afua B.,
Quansah Michael
Publication year - 2019
Publication title -
endocrinology, diabetes and metabolism
Language(s) - English
Resource type - Journals
ISSN - 2398-9238
DOI - 10.1002/edm2.70
Subject(s) - kisspeptin , medicine , endocrinology , type 2 diabetes , luteinizing hormone , diabetes mellitus , testosterone (patch) , body mass index , hormone
Kisspeptin influence on male androgens is partially understood. We aimed to evaluate serum concentrations of kisspeptin among Ghanaian men with type 2 diabetes and to identify related factors that may contribute to altering circulating kisspeptin. Methods A cross‐sectional, observational study. Sixty persons with type 2 diabetes and 60 nondiabetic controls were included in this study. Blood pressure, body mass index (BMI), kisspeptin, luteinizing hormone (LH), follicle‐stimulating hormone (FSH), total testosterone (T), glucose (FBG), glycated haemoglobin (HbA1c) and lipid levels were assessed. Results Type 2 diabetic men had lower kisspeptin and T concentrations than controls ( P = 0.001 for both). Levels of LH and FSH were, respectively, higher in diabetic men compared with their control counterparts ( P = 0.003; P = 0.017). There were negative associations within the diabetic group for kisspeptin vs age ( r = −0.590, P = 0.0001) and kisspeptin vs BMI ( r = −0.389, P = 0.002). Positive associations were also found within the diabetic group for kisspeptin vs T ( r = 0.531, P = 0.001), kisspeptin vs LH ( r = 0.423, P = 0.001) and kisspeptin vs FSH ( r = 0.366, P = 0.004). Lower T (OR = 1.473, P = 0.003) and advancing age (OR = 0.890, P = 0.004) contributed to decreased kisspeptin levels among Ghanaian males with type 2 diabetes. Conclusion Our data demonstrate that circulating kisspeptin and T concentrations are lower among men with type 2 diabetes and highlight the importance of considering kisspeptin concentrations in the management of hypogonadism and type 2 diabetes.